Combining BCL-2 Inhibitors With Androgen Blockade May Prevent Castration Resistance

Researchers at Roswell Park Comprehensive Cancer Center have identified a critical vulnerability in how prostate cancers escape standard hormonal therapy. The study reveals that when androgen receptor signaling is suppressed by ADT or AR pathway inhibitors, cancer cells compensate by ramping up BCL-2, an anti-apoptotic protein that helps them survive treatment. The findings suggest that blocking both pathways simultaneously could prevent progression to castration-resistant disease.

Under normal conditions, the androgen receptor actually suppresses BCL-2 expression at the genomic level, keeping this survival protein in check. This creates a regulatory balance where AR drives cancer growth but simultaneously limits certain survival mechanisms. When clinicians apply ADT or AR pathway inhibitors like enzalutamide or apalutamide, that suppression is lifted. BCL-2 expression increases, providing cancer cells with a potent shield against cell death that allows them to tolerate the loss of androgen signaling. This mechanism contributes directly to the development of castration-resistant prostate cancer.

The insight is mechanistically straightforward: AR blockade removes a brake on BCL-2, and the cancer exploits that change to survive. It explains why many aggressive tumors progress despite effective AR suppression, and it points to BCL-2 as a rational target to block at the same time rather than waiting to address resistance later.

The Roswell Park team tested venetoclax, an FDA-approved BCL-2 inhibitor already used in blood cancers, in combination with androgen blockade in preclinical models. The combination made aggressive prostate tumors significantly more responsive to treatment, preventing the BCL-2-driven escape that typically follows AR suppression alone. Venetoclax works by binding to BCL-2 and displacing proteins that would otherwise trigger cell death, effectively disabling the survival pathway that cancers rely on when AR signaling is removed.

This approach differs from sequential salvage therapy. Instead of waiting for resistance to emerge and then attempting to reverse it, the strategy blocks both the growth pathway and the parallel survival pathway from the outset. The logic is preemptive: if you know AR blockade will increase BCL-2, neutralize that pathway before it becomes entrenched.

The most immediate application would be in patients at high risk for rapid progression to castration resistance, such as those with high-volume metastatic disease, aggressive tumor features, or prior rapid relapse. These populations often progress quickly through standard ADT and AR inhibitors, and BCL-2 upregulation may be one driver of that trajectory. A venetoclax-plus-ADT or venetoclax-plus-AR inhibitor regimen could be tested in these groups as a frontline intensification strategy.

There are also implications for recurrent castration-resistant disease. In patients who have already progressed on AR-targeted therapy, BCL-2 levels are likely elevated. Adding venetoclax at that stage might resensitize tumors to AR blockade or to second-generation AR inhibitors, though the preclinical data suggest earlier intervention would be more effective.

The research team recently completed a phase 1b clinical trial treating metastatic castration-resistant prostate cancer patients with enzalutamide combined with venetoclax. Among 10 heavily pretreated patients (average 3 prior lines of therapy), three showed clear responses after multiple cycles. The combination demonstrated acceptable safety, though venetoclax achieved sub-therapeutic plasma levels due to drug-drug interactions with enzalutamide.

The challenge will be managing side effects. Venetoclax carries risks of tumor lysis syndrome and low blood cell counts, particularly at higher doses. Prostate cancer patients are often older with other health conditions, so dose optimization and patient selection will be critical. The balance between inhibiting BCL-2 in cancer cells versus normal blood cells will need careful evaluation in early-phase clinical trials.

Source.